Tonsillectomy and adenoidectomy remain the first choice treatment of chronic or recurrent acute infections of the upper respiratory tract in children. The aim of this study is to investigate the efficacy of the combination of thiamphenicol glycinate acetylcysteinate plus beclomethasone, administered as aerosol, in children awaiting tonsillectomy and/or adenoidectomy. The study comprised 204 children, aged 1 to 12 years, with chronic adenotonsillitis who had been listed for surgery due to obstructive symptoms and recurrent acute infections. Patients were randomized to treatment with thiamphenicol glycinate acetylcysteinate, dosage 250 mg/day in 2 administrations plus beclomethasone with a dosage of 400 JIg/day in 2 administrations, or no treatment, control group, unless required. The drugs were administered by aerosol for 10 days/month over a period of 6 months. Clinical visits were at 4, 7 and 12 months after the start of treatment. The primary efficacy outcome was the reduction in the number of patients requiring surgery. Secondary efficacy measures were the reduction of nasal obstruction, the decrease in the number of infectious episodes and the tolerability of the treatment. Aerosol treatment with thiamphenicol glycinate acetylcysteinate plus beclomethasone resulted in a significantly lower proportion of patients requiring surgery (29 of 101; 29%) compared to patients in the control group (100 of 103; 97%) (p < 0.0001). Treatment was also associated with a reduction of nasal obstruction and a decrease in the number of infectious episodes. No treatment-related adverse events were reported and the aerosol therapy proved easy to administer to children. The aerosol therapy with the combination of thiamphenicol glycinate acetylcysteinate plus beclomethasone was able to prevent or postpone surgery in a substantial percentage of patients, without adverse events. These preliminary results suggest that this novel approach could playa role in the antibiotic prophylaxis of chronic infectious diseases of the upper airways.
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With their high incidence among children, tonsillitis and adenoiditis continue to occupy a relevant place in pediatric otorhinolaryngology. The resulting hypertrophy of the tonsils and adenoids leads to obstruction of the upper airways and to otitis media. Furthermore, chronic or recurrent acute tonsillitis and adenoiditis can result in serious bacterial infections (1) (2) .
Tonsillectomy and adenoidectomy remain the first choice treatment for chronic or recurrent acute infections. Although these surgical procedures are amongst the oldest and most frequently undertaken operations in children, the indication for surgery is controversial and insufficiently stringent (3) (4) . A number of postoperative complications, including bleeding, vomiting and fever have been reported (5-6). Postoperative hemorrhages have an incidence of approximately I%, can occur a few days after surgery and, if not immediately recognized, can be life-threatening (7) (8) .
The effectiveness of tonsillectomy and/or adenoidectomy in the long-term prevention of recurrent throat infections in children has yet to be evaluated in appropriate clinical studies (3, 9) . Preliminary findings indicate only a modest benefit is achieved from the surgical approach in children moderately affected with recurrent throat infection (4) . Recent progress in the pharmacological management of throat infections has reduced the overall number of surgical interventions, however, prophylactic therapies need to be fully evaluated (10) . It has also been suggested that watchful waiting may be a reasonable approach to these childhood diseases (11) .
With the aim of exploring new pharmacological therapies for chronic and recurrent throat infections, we decided to study the efficacy of thiamphenicol glycinate acetylcysteinate (TGA) combined with beclomethasone in children with chronic tonsillitis and/or adenoiditis. Thiamphenicol, a chloramphenicol derivative, is effective in vitro against a broad spectrum of bacteria, including those frequently identified in clinical isolates from children with upper respiratory tract infections, and pathogens resistant to other antimicrobial agents, in particular penicillin-resistant pathogens (12) . The antibiotic molecule in TGA is combined with Nacetylcysteine, a molecule with mucolytic properties. TGA has been used in clinical practice for more than 30 years and its efficacy in the management of upper airway infections in adults is well established (13) (14) . Beclomethasone is a corticosteroid used for its anti-inflammatory properties in otorhinolaryngology. It has been shown in a number of studies to provide a reduction in adenoid size and/or nasal obstruction (15) (16) . Glucocorticoid therapy, effective in upper respiratory tract diseases, is currently used.
We decided to test TGA in the light of recent findings that show N-acetylcysteine interferes with the formation of bacterial biofilms and is able to disrupt biofilms (17) (18) . These structures can impair the efficacy of antimicrobial agents (19) and are involved in the processes leading to chronic and recurrent infections (20) . More importantly, they have been implicated in the persistence and intractability of pediatric otolaryngologic infections (19) (20) .
The availability of a formulation for the aerosol administration of TGA and beclomethasone is an additional favorable feature. The topical administration places the drug at the site of infection, allowing for lower doses than those necessary with systemic delivery, and subsequently, fewer adverse events. Recent progress in the production of aerosol devices able to generate particles with a diameter > 20 urn has considerably improved the selective deposition of therapeutic agents in the upper respiratory tract; this is because large particles (> 5 urn) localize at the nose-pharynx level, whilst smaller particles « 5 urn) are inhaled to the lungs and the alveoli (21) (22) (23) (24) .
In this study, we set out to evaluate the prophylactic efficacy of the aerosol administration of combined TGA plus beclomethasone in children awaiting tonsillectomy and/or adenoidectomy due to nasal obstructions and recurrent bacterial infections of the upper airways.
MATERIALS AND METHODS

Patients and study design
This randomized, open label, observational study was conducted at the Department of Otorhinolaryngology University of Insubria Varese, Italy. The study involved 204 eligible children who were referred to the Department between June 2003 and July 2004 with an indication for adenoidectomy and/or tonsillectomy. The main selection criterion was the indication for elective surgical intervention. Eligibility for surgery was based on the presence of upper airway obstruction or chronic adenotonsillitis and on the lack of response to previous pharmacological therapies, as outlined by Italian guidelines for tonsillectomy and adenoidectomy issued by a multidisciplinary panel (the Societa Italiana di Otorinolaringoiatria for chronic adenotonsillitis) (25) .
Children who needed an urgent intervention for nocturnal apnoea or other diseases were excluded. For each child a written informed consent was obtained from the parents. The study was approved by the Research Ethics Board of the hospital, where the study was conducted.
Before randomization, the medical history of each patient was carefully analyzed and the onset of oropharyngeal symptoms was established. The presence of a bacterial infection was confirmed by bacterial cultures obtained from oropharyngeal and/or nasal samples collected from the patients. Participants were randomized to receive either treatment with TGA plus beclomethasone (n = 101) for a total duration of 6 months or no treatment (control group, n = 103). Clinical and endoscopic examinations were performed at 4, 7, and 12 months from the beginning of treatment. Rhinopharynx endoscopy, using a flexible endoscope with optical fibers, was carried out to evaluate nasal obstruction.
The follow-up period was between 6 and 9 months after the treatment end. Patients requiring surgery were determined by the Italian guidelines (25) .
The primary efficacy outcome of the study was the variation in the number of patients undergoing surgery in the two treatment groups. Secondary efficacy measures were the reduction of nasal obstruction, the decrease in the number of infectious episodes in the two groups and the tolerability of the combination therapy. The infectious episodes considered were: otitis, tonsillitis, pharyngitis, adenoiditis, sinusitis, laryngitis. At each visit the number and type of infectious episodes in the previous months were recorded. Infection episodes were reported by parents during the visits and noted by the pediatrician in the child's personal health booklet.
Nasal obstruction was graded into four classes of hypertrophied adenoid rhinopharyngeal obstruction on the basis of fiber endoscopic findings: occupation of rhinopharynx only in the upper segment of the cavity (Level I); adenoids occupying 50% of the cavity (Level 2); occupation of 75% of the cavity with obstruction of choanal openings and partial closure of the tube ostium (Level 3); total obstruction of the rhinopharynx (Level 4) (26) .
The tolerability of the treatment was monitored throughout the study and adverse events, either observed by the physician or reported by the parents, were recorded in the child's personal health booklet.
Medications
Patients were treated with either twice-daily TGA (Fluimucil antibiotico, Zambon Italia) plus beclomethasone or did not receive any treatment, unless required (control group). TGA (total daily dose of 250 mg) and beclomethasone (total daily dose of 400 ug) were administered in combination as aerosol, by means of a micronized nasal douche. The combination was administered for 6 courses of 10 days/month, over a total period of 6 months.
The TGA plus beclomethasone aerosol was generated by a nebulizer specific for the upper airways (nasal cavities, rhinopharynx, oropharynx) that allowed for a thorough washing of the cavities. The aerosol was produced rapidly and continuously (5 ml/min) and the approximate diameter of the generated drug particles was 20 11m. The children were treated at home with an aerosol device after parents had been educated in the use of the device.
In cases of acute infections, patients in the control group could receive oral treatment with antibiotics and/ or corticosteroids as required and judged necessary by the physician/pediatrician. Detailed information on the treatment was recorded in the patient's personal health booklets.
Data analysis
The difference in the number of patients undergoing surgery in the two treatment groups was analyzed by the Fisher exact test. The analysis of the data concerning nasal obstruction and the number of infectious episodes was conducted on the intention-to-treat (ITT) population. Missing data from patients withdrawn from the study due to surgery was substituted by using the last-observationcarried-forward (LOCF) method. However, patients with basal data only, and who had withdrawn from the study before the visit at 4 months, were excluded from the analysis. The statistical significance of the differences between groups was established with the Student t-test.
RESULTS
Patient characteristics
The baseline characteristics of the study participants are shown in Table 1 . At study entry, there were no significant differences in the demographic or clinical characteristics of the two treatment groups. The mean age of participants was 5.6 years (range 1-12 years). Sixty percent of the patients (122/204) had adenoiditis, while 40% (82/204) had adenotonsillitis. The incidence of these conditions was similar between the two treatment groups. On average, participants had shown symptoms of adenoiditis and adenotonsillitis for 6.5 months (SD ± 2.5) prior to study entry (range 1-17 months). The bacterial species most frequently identified at study entry were Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, and Neisseria spp. All strains identified were sensitive to thiamphenicol. The flow chart of the study is shown in Fig. 1 .
Number ofpatients requiring surgery
Treatment with combined TGA plus beclomethasone, administered for 6 cycles over 6 months, resulted in a substantial reduction in the number of participants requiring surgery (Fig. 2) . Only 29% of patients (29/101) treated with TGA plus beclomethasone underwent surgery, compared to 97% of patients (100/103) receiving no treatment (p < 0.0001). Notably, in the control group a considerable proportion of surgical procedures were performed during the first three months of the study. In the same period, no patient receiving the combination drug therapy required surgery. The highest incidence of surgical intervention in the control group was between 5· and 9 months from the beginning of the study (51 patients), whereas the need for surgical intervention was delayed in the group receiving TGA plus beclomethasone (25 patients, between 7 and 12 months from study commencement). On average, patients receiving the aerosol combination therapy required surgery after 9 months (mean 9.4 months, SO ± 2.6), almost twice the time of patients receiving no treatment (5.5 months, mean 5.4, SO ± 2.7) (p < 0.0001).
Reduction ofnasal obstruction
In patients treated with the combination of TGA plus beclomethasone, nasal obstruction was significantly decreased over the course of the study, as assessed by endoscopy (Fig. 3) . At the final assessment, nasal obstruction was reduced by 38% in the treated group, but was not significantly different from baseline value in the control group (reduction of approximately 4%). The difference in reduction between the two study groups was statistically significant at all time points. Fig. 4 shows the basal mean number of infectious episodes of study participants (approximately 5 in both groups) and the mean number of infectious episodes reported during the three clinical visits. The number of infectious episodes was obtained from records in the personal health booklets.
Reduction in the number ofinfectious episodes
Over the course of the study, the frequency of infectious episodes substantially decreased in both groups, however, this decrease was significantly higher in the group treated with TGA plus beclomethasone compared with the control group (p < 0.0001 at each visit).
Tolerability
Treatment with the combination of TGA plus beclomethasone was well tolerated and no adverse events were reported during the 6 months of therapy or in the follow-up period. In addition, the aerosol formulation proved easy to administer to children. We observed no cases of epistaxis in patients.
DISCUSSION
This study shows that the combination aerosol therapy of thiamphenicol glycinate acetylcysteinate (TAG) plus beclomethasone can prevent or postpone surgery, decrease the number of infectious episodes and improve obstructive symptoms in children with chronic adenoiditis and tonsillitis. In addition, the therapy was well tolerated and no adverse events were reported.
Although all participants had been listed for surgery prior to study beginning, only 29% of the children receiving the combination therapy required surgery over the course of the study, compared with SCREENED (n = 284) 97% of children in the untreated group. Following treatment with TGA plus beclomethasone, nasal obstruction was reduced by almost 40%, whereas there was no improvement of the obstructive symptoms in the control group. The decrease in nasal obstruction and associated improvement of respiratory symptoms was presumably due to the anti-inflammatory activity of beclomethasone. The decrease in the number of infectious episodes by the combination treatment reported here is of particular relevance because the clinical outcome of adenotonsillitis is negatively affected by an increase in the number of infectious episodes that result in the increased occurrence of lymphatic tissue in the tonsils and adenoids. Interestingly, the control group also showed a decrease in the number of infectious episodes, which may have been due to the antibiotic oral treatment control patients were given if necessary.
To date, the efficacy of prophylactic therapies in the management of chronic throat infections in children has not been extensively investigated. One study, involving 179 patients (aged 2 to 20 years) with recurrent tonsillitis, found a significant reduction in the number of tonsillitis episodes following treatment with long-acting penicillin. The efficacy of the prophylactic therapy was particularly apparent in patients aged 5 to 11 years, limiting the need for surgery (27) . Moreover, in children (aged 4 to 14 years) with recurrent pharyngotonsillitis, treatment with cefpodoxime proxetil, a secondgeneration cephalosporin (100 mg twice daily, 6 days a month for 6 months), led to a significant reduction of pharyngotonsillitis episodes, both during treatment and in the 6 month follow-up period (28) . However, a separate study suggested that prophylactic therapy with the antimicrobial agent azithromycin led to a very modest decrease in tonsillitis episodes in children compared with the placebo group. The long-term treatment with azithromycin (500 mg once/week for 6 months) did not prevent acute recurrent tonsillitis (29) .
The efficacy of TGA plus beclomethasone in reducing the frequency of infectious episodes reported here was observed during the 6 months of treatment, as well as during the follow-up period (6-9 months after treatment end). This finding supports the reported antibacterial activity of TGA against pathogens most commonly implicated in infection of the upper respiratory tract and suggests that treatment with TGA may also provide an extended period of protection against recurrent infections. In light of the widely recognized relationship between bacterial biofilms and chronic otolaryngologic infections (20) , findings ofthe current study may be due to the ability ofTGA to disrupt bacterial biofilms, as demonstrated by Macchi and colleagues (18) .
The aerosol administration of the combination therapy under investigation here is likely to have contributed to its high success rate. The aerosol formulation and subsequent generation of drug particles with an average diameter of 20 urn effectively delivers the drug to the site of infection and is particularly indicated for the topical treatment of infections in the upper respiratory tract. Furthermore, aerosol treatment was well tolerated by the children, not only in terms of safety, but also due to its ease of administration. An additional advantage of this treatment is the relatively low cost of TGA, compared with the high acquisition price of more recent antimicrobial agents.
To our knowledge, this is the first reported study that uses a combination of TAG plus beclomethasone in the treatment of children with chronic upper airway infection. Although preliminary, the results presented here indicate that invasive approaches to tonsillitis and adenoiditis can be postponed, if not prevented, by the aerosol administration ofcombined TGA plus beclomethasone providing an efficient, topical treatment to the infected site. We believe that this approach supports TGA plus beclomethasone as a desirable candidate for the prophylaxis of pediatric chronic throat infections and that it deserves to be studied in more detail.
